Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.70B | 2.18B | 2.06B | 1.90B | 1.64B |
Gross Profit | 1.63B | 1.28B | 1.20B | 1.12B | 862.33M |
EBITDA | 1.61B | 1.27B | 1.39B | 970.63M | 1.13B |
Net Income | 243.14M | 306.01M | 500.45M | 505.54M | 413.56M |
Balance Sheet | |||||
Total Assets | 19.94B | 15.70B | 5.10B | 5.18B | 4.41B |
Cash, Cash Equivalents and Short-Term Investments | 119.82M | 138.99M | 7.73M | 9.88M | 2.52M |
Total Debt | 9.02B | 7.08B | 1.92B | 2.02B | 1.51B |
Total Liabilities | 10.88B | 8.77B | 2.10B | 2.19B | 1.67B |
Stockholders Equity | 8.40B | 6.35B | 2.87B | 2.84B | 2.64B |
Cash Flow | |||||
Free Cash Flow | 1.07B | 956.24M | 218.53M | 214.99M | 199.41M |
Operating Cash Flow | 1.07B | 956.24M | 258.40M | 247.56M | 233.30M |
Investing Cash Flow | -113.80M | -576.75M | -38.47M | -603.22M | -201.91M |
Financing Cash Flow | -941.42M | -337.30M | -222.07M | 363.03M | -31.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $105.70B | 174.25 | 3.52% | 1.66% | 23.31% | 36.07% | |
77 Outperform | $4.38B | 31.18 | 5.15% | 6.53% | 7.81% | 179.16% | |
75 Outperform | $11.30B | 24.47 | 10.53% | 6.87% | 10.56% | 45.37% | |
74 Outperform | $13.54B | 48.01 | 3.26% | 6.95% | 23.65% | 12.82% | |
68 Neutral | $31.23B | 203.93 | 1.36% | 2.76% | 10.00% | ― | |
64 Neutral | $6.87B | 17.44 | -1.93% | 6.95% | 4.65% | -24.33% | |
59 Neutral | $5.71B | ― | -6.83% | 7.64% | -7.26% | 18.45% |
Healthpeak Properties reported its second quarter 2025 financial results, showing a net income of $0.05 per share and a 3.5% growth in Total Merger-Combined Same-Store Cash NOI. The company executed significant lease agreements and entered into new development agreements to support outpatient expansion, while also achieving sustainability milestones and earning prestigious industry awards.
The most recent analyst rating on (DOC) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Healthpeak Properties stock, see the DOC Stock Forecast page.
John Thomas, Vice Chair of Healthpeak Properties, is set to participate in a panel discussion at the BofA Securities 2025 Healthcare Conference on May 14, 2025. This participation highlights Healthpeak’s ongoing engagement with industry events, potentially impacting its visibility and stakeholder relations.
The most recent analyst rating on (DOC) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Healthpeak Properties stock, see the DOC Stock Forecast page.
On January 30, 2025, Healthpeak Properties, Inc. adopted an Employee Stock Purchase Plan (ESPP) to allow eligible employees to purchase company stock at a discount, aligning their interests with those of shareholders. The ESPP was approved at the annual meeting on April 24, 2025, where all board nominees were elected, executive compensation was approved, and Deloitte & Touche LLP was ratified as the independent auditor.